COMPARISON OF SIMVASTATIN AND THERAPY COMBINATION OF SIMVASTATIN + UMBI EXTRACT UBIJALAR PURPLE (Ipomoea batatas L.) AGAINST CONVERTASE PROPROTEIN LEVELS SUBTILYCIN / KEXIN TYPE 9 SERUM PATIENTS DISLIPIDEMIA

Dyslipidemia is still a significant health challenge globally. Condition this is the basis of the occurrence of morbidity and mortality associated with cardiovascular disease (CVD). In humans, high levels of subtilisin convertase convertotein / kexin type 9 (PCSK9) is positively correlated with plasma low-density lipoprotein (LDL) levels. PCSK9 acts as a chaperone which encourages break down or down receptor regulation LDL (LDLR), thereby increasing LDL in plasma. The main source of PCSK9 is the liver, but PCSK9 is also expressed in several other organs. PCSK9 inhibitors have developed to increase LDL clearance through LDLR upregulation, but the price expensive. On the other hand, statins, especially simvastatin, are known to have limited due effects can increase plasma LDL cholesterol levels by causing translocation of SREBP2 which further increases PCSK9 gene expression. Anthocyanin from berries can suppress SREBP2 expression in vitro, thus causing downregulation of PCSK9. Therefore possibly purple sweet potato tuber (Ipomoea batatas L.) anthocyanin-rich Balinese cultivar potentially reducing plasma PCSK9 levels in humans. This study aims to examine the mono effect of simvastatin therapy and the combination of simvastatin + Bali purple sweet potato tuber extract for serum PCSK9 levels in clinical settings (clinical trials are limited to dyslipidemic patients). Serum PCSK9 levels will be quantified by the ELISA method, and the results are analyzed in a manner statistics with SPSS ver. 20